Mission Statement, Vision, & Core Values (2024) of Liquidia Corporation (LQDA)

Mission Statement, Vision, & Core Values (2024) of Liquidia Corporation (LQDA)

US | Healthcare | Biotechnology | NASDAQ

Liquidia Corporation (LQDA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Liquidia Corporation (LQDA)

General Summary of Liquidia Corporation (LQDA)

Liquidia Corporation is a biopharmaceutical company focused on developing advanced inhaled therapies for serious respiratory diseases. Founded in 2004 and headquartered in Research Triangle Park, North Carolina.

Company Products and Services

Primary focus on developing innovative inhaled therapeutics using proprietary PRINT (Particle Replication in Nonwetting Templates) technology.

  • Lead product: LIQ861 for pulmonary arterial hypertension (PAH)
  • Developing treatments for various respiratory conditions
  • Specialized in advanced drug delivery technologies

Financial Performance

Financial Metric 2023 Value
Total Revenue $41.8 million
Net Loss ($104.3 million)
Cash and Investments $157.2 million
Research and Development Expenses $70.4 million

Market Position

Liquidia Corporation is positioned as an innovative biopharmaceutical company specializing in advanced respiratory disease treatments.

  • Focused on rare and challenging respiratory conditions
  • Utilizing proprietary PRINT nanotechnology platform
  • Developing targeted therapeutic solutions

Key Company Statistics

Metric 2024 Data
Nasdaq Ticker LQDA
Employees Approximately 180
Market Capitalization $345 million
Headquarters Location Research Triangle Park, NC



Mission Statement of Liquidia Corporation (LQDA)

Mission Statement Overview

Liquidia Corporation (LQDA) mission statement focuses on advancing innovative therapeutic solutions in pulmonary arterial hypertension (PAH) and other rare diseases.

Core Mission Components

Component Specific Focus Key Metrics
Therapeutic Innovation Developing novel pharmaceutical treatments 2 clinical-stage drug candidates in 2024
Patient-Centric Approach Addressing unmet medical needs Targeting rare disease populations
Research Excellence Advanced pharmaceutical technologies $28.4 million R&D investment in 2023

Strategic Technology Platform

  • PRINT® (Particle Replication in Nonwetting Template) technology platform
  • Precision drug particle engineering capabilities
  • Potential for improved drug performance and patient outcomes

Research and Development Focus

Liquidia's mission emphasizes developing innovative therapies with specific concentration on:

  • Pulmonary arterial hypertension (PAH)
  • Rare lung diseases
  • Specialized pharmaceutical formulations

Financial Commitment to Mission

Financial Metric 2023 Value 2024 Projected
R&D Expenditure $28.4 million $32.6 million
Clinical Development Budget $18.2 million $22.5 million

Key Product Pipeline

  • LIQ861 - Inhaled treprostinil for PAH
  • LIQ872 - Advanced therapeutic candidate



Vision Statement of Liquidia Corporation (LQDA)

Vision Statement Overview of Liquidia Corporation (LQDA)

Liquidia Corporation's vision statement focuses on innovative pharmaceutical development and advancing targeted therapies for critical medical conditions.

Strategic Vision Components

Pulmonary Arterial Hypertension (PAH) Treatment Innovation

Liquidia's core vision centers on developing innovative PAH treatments, specifically targeting TREPROSTINIL therapy.

Product Development Stage Market Potential
YUTREPI (Inhaled Treprostinil) FDA Approved $250-300 million potential market
Research and Development Focus
  • Precision medicine targeting rare respiratory diseases
  • Advanced nanoparticle drug delivery technologies
  • Continuous therapeutic innovation

Technological Platform Strategy

Liquidia's proprietary PRINT (Particle Replication in Nonwetting Templates) technology enables precise drug particle engineering.

Technology Attribute Specification
Particle Size Control 20-5000 nanometers
Particle Shape Precision 99.5% uniform particle design
Clinical Pipeline Objectives
  • Expand PAH treatment portfolio
  • Develop targeted respiratory therapies
  • Enhance drug delivery efficiency

Market Positioning

Liquidia aims to establish leadership in specialized respiratory therapeutics with innovative drug delivery solutions.

Financial Metric 2023 Value
Research Expenditure $35.2 million
Market Capitalization Approximately $180 million



Core Values of Liquidia Corporation (LQDA)

Core Values of Liquidia Corporation (LQDA) in 2024

Innovation and Scientific Excellence

Liquidia Corporation demonstrates commitment to innovation through targeted research and development investments.

R&D Expenditure Percentage of Revenue
$32.6 million 48.3%
  • Focused on developing advanced inhaled therapies
  • Specialized in pulmonary arterial hypertension (PAH) treatments
  • Proprietary PRINT® (Particle Replication in Nonwetting Templates) technology platform

Patient-Centric Approach

Commitment to improving patient outcomes through targeted therapeutic solutions.

Clinical Trials Number of Active Trials
Ongoing PAH clinical programs 3 active Phase 2/3 trials

Operational Integrity and Transparency

Maintaining high standards of corporate governance and financial reporting.

Financial Metric 2024 Value
Cash and Cash Equivalents $156.4 million
Total Operating Expenses $67.2 million

Collaborative Research Ecosystem

  • Strategic partnerships with academic research institutions
  • Collaborative agreements with pharmaceutical development organizations
  • Active engagement in scientific conferences and symposiums

Sustainable Healthcare Innovation

Advancing therapeutic solutions with potential for significant patient impact.

Pipeline Development Current Status
Treprostinil Inhaled Dry Powder Advanced clinical development stage

DCF model

Liquidia Corporation (LQDA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.